Valuation: Steminent Biotherapeutics Inc.

Market Cap 15.43B 483M 431M 402M 365M 687M 46.74B 694M 4.83B 1.89B 23.75B 1.81B 1.77B 76.38B P/E 2024
-8.1x
P/E 2025 -20.4x
Enterprise Value 15.01B 469M 419M 391M 355M 668M 45.45B 675M 4.69B 1.84B 23.1B 1.76B 1.72B 74.27B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
58.85%
Yield 2024 *
-
Yield 2025 -
1 day-2.79%
1 week-2.54%
Current month-2.30%
1 month+144.88%
3 months+155.67%
6 months+146.14%
Current year+218.64%
1 week 170
Extreme 170
240
1 month 107
Extreme 107
240
Current year 51.4
Extreme 51.4
240
1 year 37.85
Extreme 37.85
240
3 years 15.25
Extreme 15.25
240
5 years 15.25
Extreme 15.25
240
10 years 15.25
Extreme 15.25
240
Manager TitleAgeSince
Chief Executive Officer - 2018-11-25
Director of Finance/CFO - 2021-09-14
Investor Relations Contact - 2023-09-30
Director TitleAgeSince
Director/Board Member 54 2021-12-07
Director/Board Member - 2020-09-14
Chairman - 2024-01-25
Change 5-day change 1-year change 3-year change Capi.($)
-2.79%-2.54%+319.04% - 483M
-3.19%-3.19%+44.60%+87.98% 72.13B
-15.86%-16.16%+2.68%+50.90% 49.41B
-2.39%+0.50%+3.41%+31.33% 47.24B
-6.35%-8.63%+293.39%+651.28% 40.32B
+0.30%-0.71%+29.05%+30.33% 42.61B
-3.82%-2.41%-0.27%+101.36% 39.81B
-2.13%-2.18%+7.51%+50.31% 30.52B
-3.35%-4.95%-13.38%-17.22% 23.13B
-5.27%+1.86%+12.19%-5.34% 21.09B
Average -4.48%-5.04%+69.82%+108.99% 36.67B
Weighted average by Cap. -4.85%-3.86%+46.08%+117.28%

Financials

2024 2025
Net sales - -
Net income -159M -4.96M -4.43M -4.14M -3.76M -7.07M -481M -7.14M -49.66M -19.42M -244M -18.64M -18.24M -786M -174M -5.44M -4.86M -4.53M -4.12M -7.75M -527M -7.83M -54.44M -21.29M -268M -20.44M -19.99M -861M
Net Debt -153M -4.79M -4.28M -3.99M -3.63M -6.82M -464M -6.89M -47.93M -18.75M -236M -17.99M -17.6M -758M -426M -13.32M -11.89M -11.09M -10.08M -18.96M -1.29B -19.15M -133M -52.1M -655M -50M -48.92M -2.11B
Projected Income Statement - Annual - Steminent Biotherapeutics Inc.
Logo Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The Company's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.
Employees
-
Date Price Change Volume
26-10-08 NT$191.50 -2.79% 835,469
26-10-07 NT$197.00 -1.50% 1,917,267
26-10-06 NT$200.00 -7.19% 1,811,280
26-10-05 NT$215.50 -7.11% 2,263,887
26-10-02 NT$232.00 +18.07% 3,180,252
  1. Stock Market
  2. Stocks
  3. 7729 Stock